Endocrine Practice最新文献

{"title":"Reliable monitoring of patients with MASLD using imaging: a systematic literature review and meta-analysis on measurement repeatability.","authors":"Michael Ndaa, Prashant K Pandya, Jordan Swensson, Niharika Samala, Saima Ajaz, Deepak Joshi, Walid S Ayoub, Fatih Akisik","doi":"10.1016/j.eprac.2025.09.205","DOIUrl":"https://doi.org/10.1016/j.eprac.2025.09.205","url":null,"abstract":"<p><p>As treatments for patients with metabolic dysfunction-associated steatotic liver disease (MASLD) emerge, patient eligibility assessment and monitoring is increasingly important. To assess the reliability of non-invasive imaging technologies in MASLD, we systematically reviewed the literature for studies on technical repeatability. PubMed Central and MEDLINE were searched (2015-2025) for studies in MASLD that examined the repeatability of: magnetic resonance (MR)-derived iron-corrected T1 (cT1), liver fat content (LFC) and elastography (MRE); ultrasound-based vibration controlled transient elastography liver stiffness measurement (VCTE LSM), controlled attenuation parameter (CAP) and shear wave elastography (SWE). The relative repeatability coefficient (%RC) for same-day (%RC_SD) or different-day (%RC_DD) repeat tests were summarized, and available data pooled using random-effects-meta-analysis. Our search identified 19 studies including 1,040 individuals (mean age 45 years; 43% female). The pooled random-effects average %RC_DD was 7% for cT1, 12% for LFC, 22% for MRE, 73% for VCTE LSM, and 26% for CAP, with a median interval of 14 days between repeat scans. %RC_SD values were consistently lower across all tests. In the context of MASLD monitoring, the %RC_DD for MRE and VCTE LSM overlapped with previously reported thresholds for clinically-meaningful change for treatment responders (15% and 30%, respectively). In contrast, the %RCs for cT1 and LFC were below established thresholds for clinically-meaningful change (9% and 30%, respectively). This systematic review and meta-analysis showed that cT1 and LFC are more reliable in detecting change in liver health in people living with MASLD-MASH, compared to liver stiffness. Liver stiffness measurements are less suited to monitoring individual patients.</p>","PeriodicalId":11682,"journal":{"name":"Endocrine Practice","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145225181","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Belzutifan for HIF2A-Related Pheochromocytoma and Paraganglioma: A Retrospective Study of Real-World Data.","authors":"Hussam Alkaissi, Sara Talvacchio, Alberta Derkyi, Sriram Gubbi, Alberto Pappo, Catherine Gordon, John Glod, Zhengping Zhuang, Karel Pacak","doi":"10.1016/j.eprac.2025.09.204","DOIUrl":"https://doi.org/10.1016/j.eprac.2025.09.204","url":null,"abstract":"<p><strong>Objectives: </strong>Pheochromocytoma and paraganglioma (PPGL) are rare neuroendocrine tumors of the adrenal medulla and autonomic ganglia, respectively. Germline and somatic genetic drivers are identified in up to 70% of cases. Hypoxia-inducible factor 2α (HIF-2α), encoded by the EPAS1 (HIF2A) gene, plays a central role in PPGL pathogenesis and can be stabilized directly or indirectly by pathogenic variants of several genes, collectively called pseudohypoxia cluster (or Cluster 1). Belzutifan, a small-molecule HIF-2α inhibitor, has demonstrated efficacy in von Hippel-Lindau (VHL)-related cancers, renal cell carcinoma, and few case reports of PPGL. We report real-world outcomes of belzutifan therapy in five patients with recurrent, multifocal, or metastatic EPAS1(HIF2A)-related PPGL.</p><p><strong>Methods: </strong>Clinical parameters, biochemical markers, tumor burden (RECIST 1.1), and treatment-related adverse events were carefully monitored, and recorded.</p><p><strong>Results: </strong>Four of five patients (80%) achieved a partial response, and one patient had stable disease, with no disease progression to date. The average reduction in the sum of tumor diameters was 36.8%. Chromogranin A, erythropoietin, and hemoglobin declined by 69%, 97%, and 13%, respectively, eliminating the need for therapeutic phlebotomy in patients with prior erythrocytosis. Catecholamine normalization allowed discontinuation or reduction of antihypertensive medications in two patients. Adverse events included hypoxia and anemia (1/5), mild transaminase elevation (2/5), and fatigue with weight gain (1/5).</p><p><strong>Conclusions: </strong>Belzutifan is a highly effective and well-tolerated therapeutic option for EPAS1(HIF2A)-related PPGL, producing substantial biochemical and radiographic responses, improved blood pressure control, and resolution of erythrocytosis. These findings support belzutifan as a promising genotype-driven therapy for pseudohypoxia-driven PPGL.</p>","PeriodicalId":11682,"journal":{"name":"Endocrine Practice","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145225248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Approach and Challenges for Patients with Advanced Radioiodine-Refractory Differentiated Thyroid Cancer.","authors":"Dipen C Patel, Irina Azaryan, Bhavana Konda","doi":"10.1016/j.eprac.2025.09.203","DOIUrl":"https://doi.org/10.1016/j.eprac.2025.09.203","url":null,"abstract":"<p><p>Differentiated thyroid cancers (DTC), including papillary, follicular, and oncocytic subtypes, are generally associated with an excellent prognosis due to their responsiveness to conventional therapies, including surgery, thyroid-stimulating hormone (TSH) suppression, and radioactive iodine (RAI) therapy. However, a subset of patients develops radioiodine-refractory (RAI-R) disease, characterized by tumor dedifferentiation and loss of iodine avidity, resulting in disease progression despite standard interventions. This group poses a considerable therapeutic challenge and is associated with markedly poorer outcomes. Recent advancements have transformed the treatment landscape with the emergence of systemic therapies such as anti-angiogenic multikinase inhibitors (aaMKIs) and genotype-directed therapies that offer improved disease control in advanced settings. This review consolidates the current evidence for diagnosing, evaluating, and managing advanced RAI-R DTC. It explores the pathophysiological basis of refractoriness, prognostic implications, treatment selection strategies-including active surveillance, locoregional therapies, redifferentiation approaches, and systemic therapies-and outlines practical considerations for clinicians. Future directions including immunotherapy, novel agents, and personalized therapy strategies are also discussed. Emphasis is placed on precision oncology, toxicity management, and the role of multidisciplinary care in optimizing patient outcomes.</p>","PeriodicalId":11682,"journal":{"name":"Endocrine Practice","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145212068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impairment of Bone Mineral Density in Pituitary TSH-secreting adenomas: A Retrospective, Controlled study.","authors":"Jie Liu, Yanying Li, Jifang Liu, Zhang Ye, He Liu, Xiaofeng Chai, Huijuan Zhu, Bing Xing, Wei Lian, Xiaolan Lian, Naishi Li, Lin Lu, Mei Zhang, Lian Duan, Yong Yao, Kan Deng","doi":"10.1016/j.eprac.2025.09.202","DOIUrl":"https://doi.org/10.1016/j.eprac.2025.09.202","url":null,"abstract":"<p><strong>Objective: </strong>Hyperthyroidism can harm bone health, though it is seldom reported in TSHomas. This study assessed bone mineral density (BMD) and bone turnover markers (BTM) in TSHoma patients versus euthyroid controls and evaluated the impact of surgical treatment on bone metabolism.</p><p><strong>Methods: </strong>We retrospectively reviewed 85 TSHoma patients who underwent BMD tests. Of these, 71 had baseline BMD data and were matched with 71 euthyroid healthy controls by age, sex, and BMI. BMD and BTMs were measured.</p><p><strong>Results: </strong>TSHoma patients demonstrated significantly reduced BMD compared to matched euthyroid controls across all skeletal sites, with reductions of 12.4% at the lumbar spine (1.06±0.19 vs. 1.21±0.14 g/cm², p < 0.001), 8.5% at the femoral neck (0.86±0.14 vs. 0.94±0.11 g/cm², p < 0.001), and 14.8% at the total hip (0.86±0.13 vs. 1.01±0.12 g/cm², p < 0.001). Baseline BTMs revealed elevated osteoblastic [P1NP 108 (60, 202) ng/mL] and osteoclastic markers [β-CTX 0.84 (0.62, 1.30) ng/mL]. Besides, FT3 showed strong positive correlations with BTMs: ALP (r = 0.45, p = 0.005), β-CTX (r = 0.61, p < 0.001), and P1NP (r = 0.73, p = 0.004).Following tumor resection, BTMs decreased significantly: ALP [91 (74.25, 119.5) to 71 (68, 94) U/L, p = 0.003] and β-CTX [0.75 (0.57, 0.94) to 0.22 (0.21, 0.45) ng/mL, p = 0.008]. Postoperative BMD revealed stabilization with non-significant improvements at all measured skeletal sites.</p><p><strong>Conclusions: </strong>TSHoma patients exhibit significant BMD deficits compared to euthyroid controls. Surgery effectively reduces BTMs while stabilizing BMD, preventing further deterioration rather than resoring bone density.</p>","PeriodicalId":11682,"journal":{"name":"Endocrine Practice","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145212113","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"EFFECTIVENESS OF BISPHOSPHONATES AND DENOSUMAB ON RISK OF VERTEBRAL FRACTURES IN PROSTATE CANCER PATIENTS UNDER ANDROGEN-DEPRIVATION THERAPIES: A REAL-WORLD PROSPECTIVE STUDY.","authors":"Alberto Piasentier, Maria Francesca Birtolo, Bianca Turci, Walter Vena, Alessandro Fanti, Emanuela Morenghi, Lucrezia M S Gentile, Luca Balzarini, Antonio C Bossi, Alfredo Berruti, Giovanni Lughezzani, Ciro Franzese, Fabio De Vincenzo, Marta Scorsetti, Paolo A Zucali, Andrea G Lania, Gherardo Mazziotti","doi":"10.1016/j.eprac.2025.09.201","DOIUrl":"https://doi.org/10.1016/j.eprac.2025.09.201","url":null,"abstract":"<p><strong>Objectives: </strong>This prospective study investigated the real-world effectiveness of bisphosphonates and denosumab in reducing vertebral fractures (VFs) risk induced by androgen-deprivation therapies (ADTs).</p><p><strong>Methods: </strong>226 consecutive men (mean age 74.8±6.9 years) undergoing ADT were evaluated for morphometric VFs at baseline and after 26.1±10.7 months of follow-up (range 18-64). Following enrolment, 153 patients commenced bisphosphonates (98 cases) or denosumab (55 cases), while 73 patients (32.3%) received only vitamin D and calcium supplementation. As additional control group, we enrolled 62 consecutive men (mean age 74.9±7.2 years) under chronic ADTs who had never been either evaluated or treated for skeletal fragility before study entry.</p><p><strong>Results: </strong>Incident VFs were found in 16/226 (7.1%) patients enrolled in the prospective study and in 18/62 (29.0%) control subjects (p<0.001). The risk of VFs was significantly lower in patients treated with bone active drugs as compared to those treated with vitamin D (hazard ratio 0.26, 95% confidence interval 0.09-0.73; p=0.01), without significant difference between denosumab and bisphosphonates treatment (p=0.423), although denosumab treated patients had lower BMD, higher C-terminal telopeptide of type I collagen (CTX), and more prevalent VFs. Noteworthy, incident VFs were significantly lower in patients receiving vitamin D with calcium as compared to those subjects under chronic ADT who had not been ever evaluated and treated for skeletal fragility prior to the study (12.3% vs. 29.0%; p=0.016).</p><p><strong>Conclusions: </strong>In real-world clinical practice, bisphosphonates or denosumab might be effective in reducing risk of VFs related to ADTs.</p>","PeriodicalId":11682,"journal":{"name":"Endocrine Practice","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145212123","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Automated Insulin Delivery for Minoritized and Non-Minoritized Populations with Type 1 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.","authors":"Puguh Oktavian, Citrawati Dyah Kencono Wungu, Sony Wibisono Mudjanarko, Indah Mohd Amin","doi":"10.1016/j.eprac.2025.09.198","DOIUrl":"https://doi.org/10.1016/j.eprac.2025.09.198","url":null,"abstract":"<p><strong>Objectives: </strong>Despite the efficacy of diabetes technologies, significant ethnic and racial disparities persist in the care and outcomes of individuals with type 1 diabetes. Therefore, this study evaluates the efficacy and safety of automated insulin delivery (AID) systems in non-minoritized (non-Hispanic White) and minoritized (Hispanic, non-Hispanic Black, Asian, and others) populations with type 1 diabetes.</p><p><strong>Methods: </strong>We conducted a systematic review and meta-analysis of studies identified on PubMed, Scopus, Web of Science, Cochrane Library, and ClinicalTrials.gov up to August 18, 2025. The primary outcome was the percentage of time-in-range (TIR; 3.9-10.0 mmol/L). Secondary outcomes included time-below-range (TBR), and glycated hemoglobin (HbA1c). Data were pooled as mean differences (MDs) with 95% confidence intervals (CIs).</p><p><strong>Results: </strong>Twelve studies involving 327 participants from minoritized and 1,377 non-minoritized groups were included. AID systems significantly improved TIR in both minoritized (MD 13.90% [95% CI 9.64 to 18.16], I² = 20%, p < 0.0001; high certainty) and non-minoritized groups (MD 10.66% [95% CI 9.12 to 12.21], I² = 15%, p < 0.0001; high certainty). Favorable effects were observed on HbA1c for both minoritized (MD -0.49% [95% CI -0.69 to -0.29]) and non-minoritized groups (MD -0.34% [95% CI -0.46 to -0.23]). No significant increase in severe hypoglycemia or diabetic ketoacidosis was observed.</p><p><strong>Conclusions: </strong>The AID systems improve glycemic outcomes in minoritized and non-minoritized populations with type 1 diabetes and have good safety profiles. AID systems hold promise for reducing racial and ethnic disparities in diabetes care and outcomes.</p>","PeriodicalId":11682,"journal":{"name":"Endocrine Practice","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145212133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Glucocorticoid resistance syndrome: A systematic review of the genotypes, phenotypes, and their relationships.","authors":"Shirui Wang, Wan Su, Lian Duan, Fengying Gong, Shi Chen, Linjie Wang, Hui Pan, Lin Lu, Huijuan Zhu","doi":"10.1016/j.eprac.2025.09.199","DOIUrl":"https://doi.org/10.1016/j.eprac.2025.09.199","url":null,"abstract":"<p><strong>Objectives: </strong>Generalized glucocorticoid resistance syndrome is a rare disorder caused by mutations in NR3C1. We aimed to systematically characterize its clinical, biochemical, and genetic features and quantitatively evaluate their interrelationships.</p><p><strong>Methods: </strong>We conducted a systematic literature review, identifying 67 cases from 33 published reports, and included four unreported cases from Peking Union Medical College Hospital.</p><p><strong>Results: </strong>In total, 71 cases from 43 unrelated families were analyzed, encompassing 39 distinct NR3C1 mutations. The most frequent clinical manifestations were symptoms of androgen excess (43.3%), followed by mineralocorticoid excess (38.8%) and glucocorticoid deficiency (14.9%). Elevated post-LDDST cortisol was the predominant hormonal abnormality (97.8%). Adrenal CT revealed hyperplasia or adenomas in 68.8% of evaluated patients. Compared with heterozygotes, those with homozygous/compound heterozygous mutations presented earlier (19.9 vs. 35.5 years old, P = 0.007), with markedly higher prevalence of hypertension/hypokalemia (90.9% vs. 28.6%, OR 25.00 [95% CI 2.95 -211.61], P < 0.001) and higher cortisol (3.20 [1.19, 2.63] vs. 1.40 [0.59, 1.20] × ULN, P = 0.002), ACTH (4.81 [1.71, 13.00] vs. 1.04 [1.00, 1.76] × ULN, P = 0.001), and testosterone levels (1.84 [1.34, 2.79] vs. 0.89 [0.55, 1.77] × ULN, P = 0.047). Sensitivity analyses restricted to probands confirmed these associations. Clinical manifestations correlated with elevated cortisol, and lower renin was observed in patients with hypertension/hypokalemia.</p><p><strong>Conclusion: </strong>This study provided the most comprehensive quantitative synthesis to date of glucocorticoid resistance syndrome, highlighting genotype-phenotype correlations and advancing understanding of its clinical and hormonal spectrum.</p>","PeriodicalId":11682,"journal":{"name":"Endocrine Practice","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145212156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quality of life after ethanol ablation of thyroid nodules: a one-year follow-up study.","authors":"Lorenzo Scappaticcio, Nicole Di Martino, Rita Matrone, Pamela Ferrazzano, Michela Di Nuzzo, Alessandra Volatile, Giovanni Cozzolino, Carla Carbone, Miriam Longo, Maria Ida Maiorino, Giovanni Docimo, Pierpaolo Trimboli, Giuseppe Bellastella, Katherine Esposito","doi":"10.1016/j.eprac.2025.09.197","DOIUrl":"https://doi.org/10.1016/j.eprac.2025.09.197","url":null,"abstract":"<p><strong>Objective: </strong>We aimed to evaluate thyroid-related and generic health-related quality of life (HRQoL), using the Thyroid-related Patient-Reported Outcome (ThyPRO)-39 and the Short Form health survey (SF)-36, before, six and twelve months after ethanol ablation (EA) for cystic thyroid nodules (CTNs), respectively.</p><p><strong>Methods: </strong>We conducted a prospective cohort study on consecutive patients treated with EA for cytologically benign and symptomatic CTNs at our university hospital over a period of four years. Patients were included if they had the ability to complete self-administered questionnaires in Italian and they had one year follow-up.</p><p><strong>Results: </strong>We included 104 nodules [median volume 15.6 (7.0 - 32.0) mL] from 104 patients. Six and twelve months after treatment, ThyPRO-39 scores had largely (i.e., effect size > 0.5) and significantly (P value adjusted < 0.001) improved across all scales compared with baseline. Six and twelve months after treatment, SF-36 scores had largely and significantly (P value adjusted < 0.001) improved across all scales. Nodule size, but no gender, age or body mass index, positively and significantly influenced (worsening) the general quality of life item of ThyPRO-39 at baseline, at 6-month and 12-month follow-up.</p><p><strong>Conclusions: </strong>EA of symptomatic and benign CTNs is associated with a great improvement of HRQoL scores of ThyPRO-39 and SF-36 at 6-month and 12-month follow-up. Both physical and mental domains of HRQoL are positively affected by EA of CTNs. Risk factors of remaining HRQoL deficits one year after EA need further exploration.</p>","PeriodicalId":11682,"journal":{"name":"Endocrine Practice","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145212101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing the Complexity of Inpatient Care Managed by Endocrinologists in a Tertiary Care Teaching Hospital.","authors":"Curtiss B Cook, Bithika M Thompson, Anjalee J Perrin, Janna C Castro, Alyssa K McGary, Matthew R Buras","doi":"10.1016/j.eprac.2025.09.200","DOIUrl":"https://doi.org/10.1016/j.eprac.2025.09.200","url":null,"abstract":"<p><strong>Objective: </strong>We aimed to analyze the complexity of cases managed by the inpatient endocrinology team at a tertiary care teaching hospital.</p><p><strong>Methods: </strong>Data were extracted from the electronic health records from 2019 through 2023, focusing on relative-weight (RW) data of the Medicare Severity Diagnosis-Related Groups (MS-DRG) for inpatients seen by the endocrinology, infectious diseases, cardiology, nephrology, and hospital internal medicine services. Multivariable linear regression was used to assess the association between MS-DRG RW and specialty.</p><p><strong>Results: </strong>During the 5-year time frame, the inpatient endocrinology service consulted on a total of 7,761 cases. Of these, 5,831 cases (76%) were related to diabetes, and 1,830 (24%) were for other endocrine-related diagnoses. After adjusting for year of hospital discharge, multivariable regression analyses showed that the mean MS-DRG RWs of cases evaluated by the inpatient endocrinology team were significantly higher than those of cases evaluated by infectious diseases, cardiology, nephrology, or hospital internal medicine alone (all P<.001).</p><p><strong>Conclusion: </strong>In this single-site analysis, most inpatient endocrinology consultations were for diabetes. The results showed that cases involving endocrinology had significantly higher MS-DRG RWs than those in which endocrinology was not involved. This information could have practical implications for workforce allocation and the resources needed to assure safe and effective treatment of the endocrine patient in need of complex care.</p>","PeriodicalId":11682,"journal":{"name":"Endocrine Practice","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145212104","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Info for Readers/Subscription page","authors":"","doi":"10.1016/S1530-891X(25)01014-6","DOIUrl":"10.1016/S1530-891X(25)01014-6","url":null,"abstract":"","PeriodicalId":11682,"journal":{"name":"Endocrine Practice","volume":"31 10","pages":"Pages A1-A2"},"PeriodicalIF":4.6,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145181375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}